Please sign in to follow a disease.
Malignant testicular germ cell tumor
MONDO:0003510A malignant tumor predominantly affecting young men and often associated with cryptorchidism. Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.
Also known as: testicular cancer, malignant germ cell neoplasm of testis, malignant germ cell neoplasm of the testis, malignant germ cell tumor of testis, malignant germ cell tumor of the testis, malignant germ cell tumour of testis, malignant germ cell tumour of the testis, malignant testicular germ cell neoplasm
2765 clinical trials for this condition and its sub-types, 14 tagged with Malignant testicular germ cell tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Malignant testicular germ cell tumor
-
Testis refractory cancer 13 trials
-
Testicular seminoma 8 trials
4 sub-types
- Cribriform variant testicular seminoma 0 trials
- Pseudoglandular variant testicular seminoma 0 trials
- Spermatocytic seminoma 0 trials
- Tubular variant testicular seminoma 0 trials
-
Testicular non-seminomatous germ cell cancer 3 trials · 4 incl. sub-types
3 sub-types
- Testicular embryonal carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Choriocarcinoma of testis 1 trial Sub-types →
- Testicular yolk sac tumor 1 trial Sub-types →
-
Mixed testicular germ cell cancer 2 trials
1 sub-type
-
Malignant teratoma of testis 0 trials
-
Testis polyembryoma 0 trials
Most studied deeper sub-types
-
New antibody takes aim at Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called CTIM-76 in people with advanced ovarian, testicular, or endometrial cancers that have not responded to standard treatments. CTIM-76 is a bispecific antibody designed to attach to a protein called Claudin-6 on cancer cells and he…
Phase 1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug hopes to shrink tumors in patients out of options
Disease control Recruiting nowThis study tests a new drug called BI 3820768 in adults with advanced germ cell tumors, endometrial cancer, or ovarian cancer who have run out of treatment options. The drug aims to help the immune system fight cancer. Researchers will give increasing doses to find a safe amount …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug duo aims to keep relapsed germ cell cancer in check
Disease control Recruiting nowThis study tests whether taking two drugs (zanzalintinib and oral etoposide) after high-dose chemotherapy can help keep relapsed germ cell tumors from growing. About 38 adults whose cancer has not been cured by standard treatments will participate. The goal is to see if this comb…
Phase 1/2 • Sponsor: Indiana University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Blood test may spot active testicular cancer, study seeks proof
Diagnosis Recruiting nowThis study is testing whether a blood test that measures a substance called miRNA-371 can accurately detect active testicular cancer in people who have already had their primary tumor removed. Researchers will compare the blood test results with surgical findings to see how well …
Sponsor: University of Southern California • Aim: Diagnosis
Last updated Aug 22, 2026 00:00 UTC
-
Taste steering: a new way to help chemo patients enjoy their meals
Symptom relief Recruiting nowThis study tests whether a home-based 'taste steering' program can improve food enjoyment for cancer patients undergoing chemotherapy. 201 adults with metastatic triple negative breast cancer, metastatic testicular cancer, or stage II-IV diffuse large B cell lymphoma will be rand…
Sponsor: University Medical Center Groningen • Aim: Symptom relief
Last updated Jul 17, 2026 00:00 UTC
-
Can a simple injection save your hearing during cancer treatment?
Symptom relief Recruiting nowThis early-stage trial tests whether adding Pedmark to standard cisplatin chemotherapy can prevent hearing loss in men with metastatic testicular cancer. About 80% of patients currently develop hearing damage from cisplatin. Pedmark works by neutralizing harmful molecules that ca…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Exercise program aims to beat fatigue in testicular cancer survivors
Symptom relief Recruiting nowThis study tests whether a one-year supervised physical activity program can reduce long-term fatigue in men treated for metastatic testicular cancer. 236 participants will be randomly assigned to either the exercise program or standard recommendations. The main goal is to measur…
Sponsor: Centre Leon Berard • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Bile acids may reveal testicular cancer secrets
Knowledge-focused Recruiting nowThis study looks at bile acid levels in the blood and tumor tissue of 20 men with testicular germ cell cancer. Researchers want to see if these levels can serve as markers to predict how the disease will progress and how well it responds to treatment. The goal is to improve monit…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC